FrancophonIA/ELRC3.0 huggingface dataset:
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Filgrastim ratiopharm 30 MIU/0.5 ml solution for injection or infusion
Slovenian: IME ZDRAVILA IN POT(I) UPORABE Filgrastim ratiopharm 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje
English: White blood cell counts of 100 x 109/l or greater have been observed in less than 5% of patients receiving filgrastim at doses above 0.3 MIU/kg/day (3 μg/kg/day).
Slovenian: Pri manj kot 5% bolnikov, ki prejemajo filgrastim v odmerku, večjem od 0,3 x 106i.e./kg/dan (3 μg/kg/dan), so opazili število belih krvničk, ki je enako ali večje od 100 × 109/l.
English: Filgrastim ratiopharm 30 MIU/0.5 ml: Each pre-filled syringe contains 30 million international units [MIU] (300 microgram) of filgrastim in 0.5 ml solution.
Slovenian: 1 ml raztopine za injiciranje ali infundiranje vsebuje 60 milijonov mednarodnih enot [i.e.] (600 mikrogramov) zdravila filigrastim Filgrastim ratiopharm 30 000 k.i.e./0,5 ml: ena napolnjena injekcijska brizga vsebuje 30 milijonov mednarodnih enot [i.e.] (300 mikrogramov) zdravila filgrastim v 0,5 ml raztopine.
English: Special precautions in normal donors undergoing peripheral blood progenitor cell mobilisation
Slovenian: Posebni previdnostni ukrepi pri običajnih darovalcih, pri katerih poteka zbiranje matičnih celic iz
English: Each pre-filled syringe contains 48 million international units [MIU] (480 microgram) of filgrastim in 0.8 ml (60 MIU/ml, 600 microgram/ml).
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Vsaka napolnjena injekcijska brizga vsebuje 48 milijonov mednarodnih enot [i.e.] (480 mikrogramov) zdravila filgrastim v 0,8 ml (60 000 k.i.e./ml, 600 mikrogramov /ml).
English: Vascular disorder
Slovenian: NAVODILA ZA SAMOINJICIRANJE
English: Water for injections
Slovenian: raztopina za injiciranje ali infundiranje
English: NAME OF THE MEDICINAL PRODUCT Filgrastim ratiopharm 30 MIU/0.5 ml solution for injection or infusion
Slovenian: IME ZDRAVILA Filgrastim ratiopharm 30 000 k.i.e./0,5 ml raztopina za injiciranje ali infundiranje
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Filgrastim ratiopharm 48 MIU/0.8 ml solution for injection or infusion
Slovenian: IME ZDRAVILA IN POT(I) UPORABE Filgrastim ratiopharm 48 000 k.i.e./0,8 ml raztopina za injiciranje ali infundiranje
English: During long term use, cutaneous vasculitis has been reported in 2% of SCN patients.
Slovenian: Pri 2% bolnikov s hudo kronično nevtropenijo, ki so filgrastim prejemali dalj časa, so poročali o kožnem vaskulitisu.
English: There was a low frequency (approximately 3%) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
Slovenian: Pri bolnikih s hudo kronično nevtropenijo, ki so med kliničnim preskušanjem prejemali filgrastim, je bilo malo primerov (približno 3%) mielodisplastičnih sindromov ali levkemije.
English: Subsequently the dose may be individually adjusted every 1 to 2 weeks to maintain the average neutrophil count between 1.5 x 109/l and 10 x 109/l.
Slovenian: Za to, da bi povprečno število nevtrofilcev ostalo med 1,5 x 109/l in 10 x 109/l, se odmerek lahko prilagaja glede na posameznika vsak teden oz. vsaka dva tedna.
English: The recommended starting dose is 1.2 MIU (12 μg)/kg/day subcutaneously as a single dose or in
Slovenian: (12 μg)/kg/dan subkutano v enkratnem odmerku ali v
English: Common but generally asymptomatic cases of splenomegaly and very rare cases of splenic rupture have been reported in healthy donors and patients following administration of G-CSFs (see section
Slovenian: Pri zdravih darovalcih in bolnikih, ki so prejemali faktor, ki spodbuja rast granulocitnih kolonij, so poročali o pogostih, a v splošnem asimptomatskih primerih splenomegalije, zelo redko pa o primerih
English: Undesirable effect Spleen disorder
Slovenian: Neželeni učinek obolenje vranice mišičnoskeletna bolečina
English: Sickle cells crises, in some cases fatal, have been reported with the use of filgrastim in subjects with sickle cell disease.
Slovenian: Poročali so o srpastoceličnih krizah, ki so bile za nekatere osebe s srpasto anemijo, ki so prejemale filgrastim, usodne.
English: However, during the period of administration of filgrastim for PBPC mobilisation, filgrastim should be discontinued or its dosage should be reduced if the leukocyte
Slovenian: Če bolniku prejema filgrastim za zbiranje matičnih celic v periferni krvi, je potrebno zdravljenje s filgrastimom prenehati ali pa, v primeru da število levkocitov preseže vrednost 70 x 109/l, zmanjšati odmerek.
English: Transient thrombocytopenia (platelets < 100 x 109/l) following filgrastim administration and leukapheresis was observed in 35% of subjects studied.
Slovenian: Pri 35% oseb, ki so sodelovale v preskušanju, so po odmerjanju filgrastima in po levkaferezi opazili prehodno trombocitopenijo (št. trombocitov < 100 x 109/l).
English: Rare
Slovenian: Redki:
English: Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm3.
Slovenian: Pri bolnikih, pri katerih pride do trombocitopenije, kar pomeni, da je število trombocitov stalno < 100.000/mm3, je potrebno razmisliti o začasni prekinitvi zdravljenja ali o zmanjšanju odmerka
English: Nausea/Vomiting
Slovenian: Zelo pogosti slabost/bruhanje
English: Filgrastim should be diluted in 20 ml of glucose 50 mg/ml (5%) solution for infusion (see section 6.6 for instructions on dilution).
Slovenian: Filgrastim je potrebno razredčiti v 20 ml glukoze 50 mg/ml (5%) raztopini za infundiranje (postopek
English: Long term treatment with Filgrastim ratiopharm may be required to maintain a normal number of white cells in your blood.
Slovenian: Zato da bi število belih krvničk v vaši krvi ostalo na običajni ravni, bo morda potrebno dolgotrajno zdravljenje z zdravilom Filgrastim ratiopharm.
English: Decreased glucose, elevated alkaline phosphatase, elevated LDH, hyperuricaemia
Slovenian: Presnovne in prehranske motnje Zelo pogosti zvišanje alkalne fosfataze, laktatne dehidrogenaze (LDH), sečne kisline
English: Each pre-filled syringe contains 48 MIU (480 µg) of filgrastim in 0.8 ml solution for injection or
Slovenian: (480 µg) filgrastima v 0,8 ml raztopine za
English: White cells are important as they
Slovenian: Bele krvničke so pomembne, saj vašemu telesu pomagajo, da se bori proti okužbam.
English: In patients with severe chronic neutropenia (SCN)
Slovenian: Posebni previdnostni ukrepi pri bolnikih s hudo kronično nevtropenijo
English: Always use Filgrastim ratiopharm exactly as your doctor has told you.
Slovenian: KAKO UPORABLJATI ZDRAVILO Filgrastim ratiopharm Pri uporabi zdravila Filgrastim ratiopharm natančno upoštevajte zdravnikova navodila.
English: MARKETING AUTHORISATION HOLDER ratiopharm GmbH
Slovenian: SHRANJEVANJE ZDRAVILA Filgrastim ratiopharm
English: Do not use any Filgrastim ratiopharm that is left in the syringe.
Slovenian: Zdravila Filgrastim ratiopharm, ki morebiti ostane v injekcijski brizgi, ne smete več uporabiti.
English: Special precautions in recipients of allogeneic PBPC mobilised with filgrastim
Slovenian: Pri nekaterih bolnikih s srpasto anemijo, ki so prejemali filgrastim, je
English: Deutschland ratiopharm GmbH Tel: +49 731 402 02
Slovenian: Malta ratiopharm GmbH, Il Ġermanja Tel: +49 731 402 02
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer Carton
Slovenian: PODATKI NA ZUNANJI OVOJNINI Zunanja ovojnina
English: Therefore, filgrastim is not indicated for use in these conditions.
Slovenian: Zato ga pri takšnih bolnikih ne smete uporabljati.
English: Each pre-filled syringe contains 30 MIU (300 µg) of filgrastim in 0.5 ml solution for injection or
Slovenian: (300 µg) filgrastima v 0,5 ml raztopine za
English: Once the neutrophil nadir has been passed the daily dose of filgrastim should be titrated against the
Slovenian: Ko najnižje število nevtrofilcev preide na višji nivo, je treba koncentracijo dnevnega odmerka filgrastima prilagoditi, da bi se izognili nihanju v številu nevtrofilcev, kot kaže spodnja preglednica:
English: Headache
Slovenian: SERIJE
English: > 1.0 x 109/l for 3 consecutive days
Slovenian: 0,2 x 106 i.e. (2 μg).
English: 0.375 ml (40 µg/ml) 1 pre-filled pen
Slovenian: 0,375 ml (40 µg/ml) 1 napolnjena brizga
English: 0.65 ml (200 µg/ml) 4 pre-filled pens
Slovenian: 0,65 ml (200 µg/ml) 4 napolnjene brizge
English: 0.65 ml (200 µg/ml) 1 pre-filled pen
Slovenian: 0,65 ml (200 µg/ml) 1 napolnjena brizga
English: 0.375 ml (40 µg/ml) 4 pre-filled syringes with needle guard
Slovenian: 0,375 ml (40 µg/ml) 4 napolnjene injekcijska brizge s ščitnikom igle
English: 0.65 ml (200 µg/ml) 4 pre-filled syringes with needle guard
Slovenian: 0,65 ml (200 µg/ml) 4 napolnjene injekcijska brizge s ščitnikom igle
English: 0.375 ml (40 µg/ml) 1 pre-filled syringe with needle guard
Slovenian: 0,375 ml (40 µg/ml) 1 napolnjena injekcijska brizga s ščitnikom igle
English: 0.65 ml (200 µg/ml) 1 pre-filled syringe with needle guard
Slovenian: 0,65 ml (200 µg/ml) 1 napolnjena injekcijska brizga s ščitnikom igle
English: The full EPAR and risk management plan summary for Aripiprazole Mylan Pharma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Aripiprazol Mylan Pharma sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The name of the medicine was changed to Aripiprazole Mylan Pharma on 3 June 2016.
Slovenian: Ime zdravila je bilo spremenjeno v Aripiprazol Mylan Pharma 3. junija 2016.
English: Aripiprazole Mylan Pharma is available as tablets (5, 10, 15 and 30 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Aripiprazol Mylan Pharma je na voljo v obliki tablet (5, 10, 15 in 30 mg) in se izdaja le na recept.
English: This is a summary of the European public assessment report (EPAR) for Aripiprazole Mylan Pharma.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Aripiprazol Mylan Pharma.
English: In addition, the company that markets Aripiprazole Mylan Pharma will provide educational materials to be supplied to patients or their caregivers and to doctors to explain the safe use of the medicine in patients between 13 and 17 years.
Slovenian: Poleg tega bo družba, ki trži zdravilo Aripiprazol Mylan Pharma, priskrbela izobraževalno gradivo, ki ga bodo prejeli bolniki ali njihovi negovalci ter zdravniki, v katerem bo pojasnjena varna uporaba zdravila pri bolnikih, starih od 13 do 17 let.
English: Aripiprazole Mylan Pharma is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Slovenian: Zdravilo Aripiprazol Mylan Pharma se uporablja pri odraslih za zdravljenje zmernih in hudih maničnih epizod ter za preprečevanje pojava novih maničnih epizod pri odraslih, ki so se v preteklosti že odzvali na zdravilo.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aripiprazole Pharmathen on 30 June 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Aripiprazol Pharmathen, veljavno po vsej Evropski uniji, izdala 30. junija 2015.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Aripiprazole Mylan Pharma has been shown to have comparable quality and to be bioequivalent to Abilify.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Aripiprazol Mylan Pharma primerljivo raven kakovosti kot zdravilo Abilify ter da mu je biološko enakovredno.
English: The Committee recommended that Aripiprazole Mylan Pharma be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Aripiprazol Mylan Pharma odobri za uporabo v EU.
English: Because Aripiprazole Mylan Pharma is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Aripiprazol Mylan Pharma generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The dose should be adjusted in patients who are taking other medicines that affect the way Aripiprazole Mylan Pharma is broken down in the body.
Slovenian: Odmerek je treba prilagoditi pri bolnikih, ki jemljejo druga zdravila, ki vplivajo na presnovo zdravila Aripiprazol Mylan Pharma v telesu.
English: Aripiprazole Mylan Pharma is used in patients with the following mental illnesses:
Slovenian: Zdravilo Aripiprazol Mylan Pharma se uporablja pri bolnikih z naslednjimi duševnimi boleznimi:
English: This means that Aripiprazole Mylan Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Abilify.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer
English: What measures are being taken to ensure the safe and effective use of Aripiprazole Mylan Pharma?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Aripiprazol Mylan Pharma?
English: For more information about treatment with Aripiprazole Mylan Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Aripiprazol Mylan Pharma preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: A risk management plan has been developed to ensure that Aripiprazole Mylan Pharma is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Aripiprazol Mylan Pharma je bil pripravljen načrt obvladovanja tveganj.
English: Aripiprazole Mylan Pharma is used in patients aged 15 years or over;
Slovenian: Zdravilo Aripiprazol Mylan Pharma se uporablja pri bolnikih, starih 15 let ali več;
English: Because Aripiprazole Mylan Pharma is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Abilify.
Slovenian: Ker je zdravilo Aripiprazol Mylan Pharma generično zdravilo, so bile študije pri ljudeh omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Abilify.
English: What are the benefits and risks of Aripiprazole Mylan Pharma?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Aripiprazol Mylan Pharma?
English: For treating manic episodes in bipolar disorder, the recommended starting dose in adults is 15 mg by mouth once a day, either on its own or in combination with other medicines.
Slovenian: Za zdravljenje maničnih epizod pri bipolarni motnji pri odraslih je priporočeni začetni odmerek 15 mg peroralno enkrat na dan, ki se jemlje bodisi kot samostojno zdravilo bodisi v kombinaciji z drugimi zdravili.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Aripiprazole Mylan Pharma, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: Aripiprazole Mylan Pharma contains the active substance aripiprazole and is a ‘generic medicine'.
Slovenian: Zdravilo Aripiprazol Mylan Pharma vsebuje zdravilno učinkovino aripiprazol in je „generično zdravilo“.
English: For practical information about using Aripiprazole Mylan Pharma, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Aripiprazol Mylan Pharma naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Previously known as Aripiprazole Pharmathen.
Slovenian: Prej znano kot Aripiprazole Pharmathen.
English: The active substance in Aripiprazole Mylan Pharma, aripiprazole, is an antipsychotic medicine.
Slovenian: Zdravilna učinkovina v zdravilu Aripiprazol Mylan Pharma, aripiprazol, je antipsihotik.
English: Other information about Aripiprazole Mylan Pharma
Slovenian: Druge informacije o zdravilu Aripiprazol Mylan Pharma
English: What is Aripiprazole Mylan Pharma and what is it used for?
Slovenian: Kaj je zdravilo Aripiprazol Mylan Pharma in za kaj se uporablja?
English: For treating manic episodes in patients aged between 13 and 17 years, the starting dose is 2 mg a day (using an aripiprazole product available in liquid form), which is gradually increased to the recommended dose of 10 mg once a day.
Slovenian: Za zdravljenje maničnih epizod pri bolnikih, starih od 13 do 17 let, se jemlje začetni odmerek 2 mg na dan (pri čemer se uporablja zdravilo z aripiprazolom v tekoči obliki), ki se postopoma povečuje na priporočeni odmerek 10 mg enkrat na dan. Zdravljenje ne sme biti daljše od 12 tednov.
English: Why is Aripiprazole Mylan Pharma approved?
Slovenian: Zakaj je bilo zdravilo Aripiprazol Mylan Pharma odobreno?
English: How is Aripiprazole Mylan Pharma used?
Slovenian: Kako se zdravilo Aripiprazol Mylan Pharma uporablja?
English: Aripiprazole Mylan Pharma is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Slovenian: Zdravilo se uporablja tudi za zdravljenje zmernih do hudih maničnih epizod pri bolnikih, starih 13 let ali več, v obdobju do 12 tednov.
English: How does Aripiprazole Mylan Pharma work?
Slovenian: Kako zdravilo Aripiprazol Mylan Pharma deluje?
English: How has Aripiprazole Mylan Pharma been studied?
Slovenian: Kako je bilo zdravilo Aripiprazol Mylan Pharma raziskano?
English: A comprehensive review of the published data was provided.
Slovenian: Predložen je bil izčrpen pregled objavljenih podatkov.
English: 63-100 Śrem POLAND
Slovenian: 63-100 Śrem POLJSKA
English: aureus (skin disease).
Slovenian: aureus (bolezen kože).
English: Efficacy in target animals
Slovenian: Učinkovitost pri ciljnih živalih
English: The Committee was also asked to recommend whether the marketing authorisations should be maintained, varied, suspended or withdrawn.
Slovenian: Odbor je bil prav tako zaprošen za priporočilo, ali naj se dovoljenje za promet z zdravilom ohrani, spremeni, začasno umakne ali ukine.
English: No specific risk to animal health was identified.
Slovenian: Opredeljeno ni bilo nobeno posebno tveganje za zdravje živali.
English: 17170 Amer SPAIN
Slovenian: 17170 Amer ŠPANIJA
English: 2050-501 Vila Nova Da Rainha PORTUGAL
Slovenian: 2050-501 Vila Nova Da Rainha PORTUGALSKA
English: Thus, it was possible for the animals to receive the indicated dose of antibiotic.
Slovenian: Zato so lahko živali prejele indicirani odmerek antibiotika.
English: List of the names, pharmaceutical form, strength of the veterinary medicinal products, animal species, route of administration, applicant/marketing authorisation holders in the Member States
Slovenian: Seznam imen, farmacevtskih oblik, jakosti zdravila za uporabo v veterinarski medicini, živalskih vrst, poti uporabe, predlagateljev/imetnikov dovoljenja za promet z zdravilom v državah članicah
English: Risk for public health
Slovenian: Tveganje za javno zdravje
English: Fluoroquinolones have been authorised for use in these species for many years.
Slovenian: Uporaba fluorokinolonov pri teh živalskih vrstah je dovoljena že veliko let.
English: In summary it may be concluded that today there is sufficient susceptibility to allow adequate treatment against the target animal pathogen Pasteurella.
Slovenian: Če povzamemo, mogoče je sklepati, da zdaj obstaja zadostna občutljivost, ki omogoča ustrezno zdravljenje ciljnega živalskega patogena Pasteurella.
English: The treatment did not affect the estimated water consumption of animals (about 100 ml/kg body weight).
Slovenian: Zdravljenje ni vplivalo na ocenjeno porabo vode pri živalih (približno 100 ml/kg telesne mase).
English: These species account for 85% of the animal (meat) production whilst e.g. rabbits only account for 0.7% of the French animal production (EMA, 2011)6, France being one of the biggest rabbit producers in the EU.
Slovenian: Te živalske vrste pomenijo 85 % reje živali (za meso), medtem ko imajo na primer kunci le 0,7-odstoten delež v francoski reji živali (EMA, 2011)6, pri čemer je Francija ena od največjih držav za vzrejo kuncev v EU.
English: Of the strains examined, 86.67% were susceptible to enrofloxacin, 10% were intermediate and 3.33% were resistant.
Slovenian: Od preučevanih sevov jih je bilo 86,67 % občutljivih za enrofloksacin, 10 % jih je bilo vmesno občutljivih, 3,33 % pa jih je bilo odpornih.
English: • Official and local antimicrobial policies should be taken into account when the product is used.
Slovenian: • pri uporabi zdravila je treba upoštevati uradne in lokalne protimikrobne politike;
English: A second pharmacokinetic study was carried out in order to confirm the dose.
Slovenian: Za potrditev tega odmerka je bila opravljena še ena farmakokinetična študija.
English: 411800-282 Lisboa PORTUGAL
Slovenian: 411800-282 Lisboa PORTUGALSKA
English: Sensitivity of various strains of P. multocida was analysed in Spain between 2009 and 2011 and the antibiogram results showed that of a total of 61 P. multocida isolates all 61 strains were sensitive.
Slovenian: Občutljivost različnih sevov P. multocida je bila analizirana v Španiji med letoma 2009 in 2011, rezultati antibiograma pa so pokazali, da je bilo od skupaj 61 izolatov P. multocida občutljivih vseh 61 sevov.
English: • Whenever possible, fluoroquinolones should only be used based on susceptibility testing.
Slovenian: • fluorokinolone je treba po možnosti uporabljati le na podlagi preskušanja občutljivosti;
English: Furthermore, as a consequence of restriction on availability, off-label use could be anticipated and this would compromise correct monitoring of use and reporting of adverse reactions.
Slovenian: Poleg tega bi se zaradi omejitve razpoložljivosti lahko pričakovala nenamenska uporaba (off-label use), kar bi ogrozilo ustrezno spremljanje uporabe in poročanje o neželenih učinkih.
English: Unfortunately, there is insufficient information on the interpretation criteria used on the RESAPATH annual reports.
Slovenian: Žal pa ni dovolj podatkov o merilih za razlago, ki so bila uporabljena v letnih poročilih mreže RESAPATH.
English: The pharmacokinetic/pharmacodynamic relationship was discussed in relation to the dosage regimens for the clinical trials provided.
Slovenian: O farmakokinetičnem/farmakodinamičnem razmerju se je razpravljalo v povezavi z režimi odmerjanja za predložena klinična preskušanja.
English: The current knowledge regarding the occurrence of antimicrobial resistance in food animals and the influence of the animal production on its transmission is incomplete.
Slovenian: Sedanje znanje o pojavu protimikrobne odpornosti pri živalih za hrano in vplivu reje živali na njen prenos je nepopolno.
English: Gran Via Carlos III 98 - 7ª 08028 Barcelona SPAIN
Slovenian: Gran Via Carlos III 98 - 7ª 08028 Barcelona ŠPANIJA
English: The species for which spread of MRSA would be important is therefore mainly swine (high prevalence) and companion animals (close contact).
Slovenian: Vrste, pri katerih bi bilo širjenje MRSE pomembno, so torej večinoma svinje (velika razširjenost) in hišne živali (tesen stik).
English: Several MIC data on P. multocida isolated from clinical samples from 30 Spanish rabbit farms in 2006 and 2007 were provided.
Slovenian: Predloženih je bilo več podatkov o MIC za P. multocida, izoliranem iz kliničnih vzorcev iz 30 španskih kunčjih farm v letih 2006 in 2007.